Reproductive hormone stability with prolonged intranasal oxytocin in adults with obesity
Authors' conclusion
In our study, eight-weeks of intranasal oxytocin administration did not impact prolactin or sex steroid levels, or menstrual cycle length, providing preliminary support for reproductive safety of oxytocin-based therapeutics in adults with obesity.
Study context
- Population
- Adults with obesity (52% females)
- Participants
- 61 adults
- Comparison
- Intranasal oxytocin vs placebo for 8 weeks
- Primary endpoint
- Pre- and post-treatment fasting estradiol, testosterone and prolactin
- Follow-up
- 8 weeks
Methodological detailslongitudinal, placebo-controlled
- Longitudinal
- Placebo-controlled
Primary result
As reported in the abstract
Prolactin and sex steroid levels
- Oxytocin vs placebo did not differ for effects on prolactin or sex steroid levels
- Oxytocin vs Placebo: p's ≥ 0.140
Further findings
| Outcome | P value |
|---|---|
| On-treatment mean menstrual cycle length (exploratory) | P = 0.234 |
On-treatment mean menstrual cycle length (exploratory)
- Menstrual cycle length did not differ across groups
Original publication
Reproductive hormone stability with prolonged intranasal oxytocin in adults with obesity. Int J Obes (Lond). Published 9 April 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →